Humanigen Inc logo

HGEN

Humanigen Inc

$0.34

Earnings Summary

Revenue
$1.04Mn
Net Profits
$-21.28Mn
Net Profit Margins
-2053.86%

Highlights

Revenue:

Humanigen Inc’s revenue jumped 113.17% since last year same period to $1.04Mn in the Q1 2022. On a quarterly growth basis, Humanigen Inc has generated -0.1% fall in its revenue since last 3-months.

Net Profits:

Humanigen Inc’s net profit jumped 67.55% since last year same period to $-21.28Mn in the Q1 2022. On a quarterly growth basis, Humanigen Inc has generated 36.56% jump in its net profits since last 3-months.

Net Profit Margins:

Humanigen Inc’s net profit margin jumped 84.78% since last year same period to -2053.86% in the Q1 2022. On a quarterly growth basis, Humanigen Inc has generated 36.5% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Humanigen Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.3
EPS Estimate Current Year
-0.3

Highlights

EPS Estimate Current Quarter:

Humanigen Inc’s earning per share (EPS) estimates for the current quarter stand at -0.3 - a 34.78% jump from last quarter’s estimates.

EPS Estimate Current Year:

Humanigen Inc’s earning per share (EPS) estimates for the current year stand at -0.3.

Key Ratios

Key ratios of the Humanigen Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.32
Return on Assets (ROA)
-1.08
Return on Equity (ROE)
-21.65
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Humanigen Inc’s earning per share (EPS) jumped 74.4% since last year same period to -0.32 in the Q1 2022. This indicates that the Humanigen Inc has generated 74.4% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Humanigen Inc’s return on assets (ROA) stands at -1.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Humanigen Inc’s return on equity (ROE) stands at -21.65.

Dividend Per Share (DPS):

Humanigen Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.46
-0.32
30.43%

Company Information

Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

Organisation
Humanigen Inc
Headquarters
Burlingame, California, US
Employees
10
Industry
Biotechnology
CEO
Cameron Durrant